[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"idiopathic-membranous-nephropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:idiopathic-membranous-nephropathy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100624038","phase-4-rivaroxaban-in-idiopathic-membranous-nephropathy-100624038",false,"NCT07404436","Rivaroxaban in Idiopathic Membranous Nephropathy","Efficacy of Rivaroxaban for Thromboprophylaxis in Idiopathic Membranous Nephropathy: A Prospective, Single-Center, Randomized Controlled Trial","Inclusion Criteria:\n\nAge 18-80 years, either sex. Kidney biopsy findings on both light microscopy and electron microscopy consistent with idiopathic membranous nephropathy (IMN).\n\nIMN patients at high risk of thrombosis: meeting the diagnostic criteria for nephrotic syndrome and having serum albumin \\\u003C25 g\u002FL. Normal renal function (normal creatinine clearance).\n\nExclusion Criteria:\n\nPrior thrombotic events, such as pulmonary embolism, renal vein thrombosis, or lower-extremity deep vein thrombosis.\n\nPulmonary diseases that may affect the accuracy of ventilation-perfusion (V\u002FQ) scanning for diagnosing pulmonary embolism, such as pulmonary infection\u002Finflammation, lung tumors, or chronic obstructive pulmonary disease.\n\nInability to undergo V\u002FQ scanning, e.g., right-to-left congenital cardiac shunt, prior allergy to radiopharmaceuticals, or inability to cooperate with the examination.\n\nClinically significant active bleeding. Pregnant or breastfeeding women. Acute myocardial infarction and\u002For acute stroke, or atrial fibrillation. Active infection or active malignancy. Coagulation abnormalities; hepatic dysfunction (aminotransferases ≥3× the upper limit of normal); or thrombocytopenia (platelet count \\\u003C100×10\\^9\u002FL).","ALL","18 Years","80 Years",{"count":20,"type":21},134,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Through a prospective, single-center, randomized controlled trial, we aim to determine the thromboprophylactic efficacy of rivaroxaban in patients with idiopathic membranous nephropathy (IMN). IMN patients at high risk of thrombosis and low risk of bleeding will be enrolled and randomly assigned to a rivaroxaban group or a control group (receiving warfarin). Prophylactic anticoagulation will be administered with rivaroxaban or warfarin accordingly. Over the 6 months following initiation of prophylactic anticoagulation, the incidence of the primary efficacy endpoint (a composite of pulmonary embolism, deep vein thrombosis, and lower-extremity deep vein thrombosis) and the safety endpoint (bleeding events) will be compared between the two groups.",[27],"Idiopathic Membranous Nephropathy","RECRUITING","2026-02-05",{"date":31,"type":32},"2026-02-11","ACTUAL",{"date":34,"type":32},"2024-01-05",{"date":36,"type":21},"2026-12-31",{"name":38,"class":39},"Beijing Friendship Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":40},"100419745","phase-3-different-immunosuppressive-treatment-in-imn-100419745","NCT04745728","Different Immunosuppressive Treatment in iMN","Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective Cohort","Inclusion Criteria:\n\n* idiopathic membranous nephropathy\n* Female, must be post-menopausal, sterile or have effective contraception\n* must be off steroid or mycophenolate mofetil for \\>1 month and alkylating agents for or RTX\\> 6 months\n* Angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for ≥ 3 months with controlled blood pressure prior to beginning of immunosuppressive therapy or if patients are intolerant to ACEI\u002FARB.\n* proteinuria ≥4g\u002F24h and decreased ≤ 50% from baseline\n\nExclusion Criteria:\n\n* presence of active infection or a secondary cause of membranous nephropathy\n* proteinuria associated with diabetic nephropathy\n* pregnancy or breast feeding\n* history of resistance to rituximab or alkylating agents or corticosteroid\n* Patients who previously achieved remission after treatment of rituximab or alkylating agents but relapsed off rituximab or alkylating agents after 6 months are eligible.",{"count":49,"type":21},200,[51],"PHASE3","The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)",[27],"2025-12-02",{"date":56,"type":32},"2025-12-09",{"date":58,"type":32},"2021-04-14",{"date":60,"type":21},"2029-12",{"name":62,"class":39},"Peking Union Medical College Hospital",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":40},"100503750","phase-4-effect-of-huaier-granule-on-the-treatment-of-idiopathic-membranous-nephropathy-100503750","NCT05839314","Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy","Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy: a Multicenter, Randomized, Open-label, Parallel Controlled Study","Inclusion Criteria:\n\n* Renal biopsy was performed before randomization and pathologically diagnosed as idiopathic membranous nephropathy;\n* Anti-phospholipase a2 receptor (PLA2R) antibody is positive;\n* Aged from 18 to 75, either sex;\n* Tolerable doses of RASI were received for ≥4 weeks before randomization, nephrotic syndrome was not in remission and 24-hour urinary protein level was ≥3.5g\u002F24h and \\\u003C 8.0g\u002F24h;\n* The eGFR≥45ml\u002Fmin\u002F1.73m2 (Measured at least twice in 2 weeks);\n* The patient is willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* Diagnosed as secondary membranous nephropathy;\n* Rapidly progressive membranous nephropathy (eGFR decreased by 50 % compared with the baseline level within 3 months);\n* Receiving renal replacement therapy;\n* Diabetes and glycosylated hemoglobin (HbA1c) levels ≥ 7.0%;\n* Hypertension is not well controlled (systolic blood pressure\\>160mmHg or diastolic blood pressure\\>100mmHg);\n* The level of serum albumin≤20g\u002FL;\n* Resistance to treatment with CsA or other CNI, rituximab (RTX) or alkylating agents; complete remission or partial remission was obtained after treatment with CNI, RTX, or alkylating agents but there was a history of relapse within 3 months；\n* Suspected infection by imaging and\u002For laboratory tests;\n* Infectious diseases, such as hepatitis B, hepatitis C, AIDS, tuberculosis;\n* History of malignant tumor;\n* Hepatic dysfunction: aspartate aminotransferase (AST) concentration and alanine aminotransferase (ALT) concentration of \\> 1.5 × upper limit of normal;\n* Allergic to Huaier granule or Ciclosporin soft capsules;\n* Previous CNI treatment was ineffective;\n* Complicate with any diseases that may affect efficacy and safety evaluation;\n* Pregnant or lactating women, and patients (male or female) with fertility plans or unwilling to take effective contraceptive measures;\n* Participating in other clinical trials or participated in other clinical studies within 3 months;\n* According to the researchers, patients have diseases or conditions that increase the difficulty of enrollment or probability of loss to follow-up, such as mental illness, frequent changes in residence and work, etc.","75 Years",{"count":72,"type":21},480,[24],"This is a prospective, multicenter, randomized, open-label, parallel controlled study. The purpose of this study is to evaluate the efficacy and safety of Huaier granule on the treatment of idiopathic membranous nephropathy comparing with Ciclosporin soft capsules.",[76,77,27],"Nephropathy","Glomerular Diseases",[79,80,81],"Huaier granule","Ciclosporin","Idiopathic membranous nephropathy","2024-06-02",{"date":84,"type":32},"2024-06-04",{"date":86,"type":32},"2023-05-09",{"date":88,"type":21},"2027-07-01",{"name":90,"class":39},"Chinese PLA General Hospital"]